Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
ANEB

ANEB - Anebulo Pharmaceuticals, Inc. Stock Price, Fair Value and News

$0.86-0.05 (-5.49%)
Market Closed

22/100

ANEB

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

22/100

ANEB

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$0.86

Target 3M

$0.97

Target 6M

$0.91

ANEB Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ANEB Price Action

Last 7 days

-21.1%

Last 30 days

-13.1%

Last 90 days

-67.4%

Trailing 12 Months

-44.2%

ANEB RSI Chart

ANEB Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ANEB Valuation

Market Cap

35.3M

Price/Earnings (Trailing)

-4.19

Price/Sales (Trailing)

51.36

EV/EBITDA

-19.63

Price/Free Cashflow

-5.96

ANEB Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$0.86

Target 3M

$0.97

Target 6M

$0.91

ANEB Fundamentals

ANEB Revenue

Revenue (TTM)

864.0K

ANEB Earnings

Earnings (TTM)

-8.4M

Earnings Growth (Yr)

1.93%

Earnings Growth (Qtr)

-0.63%

ANEB Profitability

EBT Margin

-1905.95%

Return on Equity

-86.7%

Return on Assets

-78.89%

Free Cashflow Yield

-16.79%

ANEB Investor Care

Shares Dilution (1Y)

58.43%

Diluted EPS (TTM)

-0.22

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2025705.7K864.0K00
2024222.8K0389.0K547.3K
202371.1K92.4K0163.5K
202207.3K28.6K49.9K
202101.0K00
Get all data in R, Python etc through our Historical Stock Data APIs

About Anebulo Pharmaceuticals, Inc.

ANEB
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. The company was incorporated in 2020 and is based in Lakeway, Texas.
 CEO
 WEBSITEanebulo.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES4

Anebulo Pharmaceuticals, Inc. Frequently Asked Questions

ANEB is the stock ticker symbol of Anebulo Pharmaceuticals, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Anebulo Pharmaceuticals, Inc. is 35.33 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check ANEB's fair value in chart for subscribers.

The fair value guage provides a quick view whether ANEB is over valued or under valued. Whether Anebulo Pharmaceuticals, Inc. is cheap or expensive depends on the assumptions which impact Anebulo Pharmaceuticals, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ANEB.

As of Wed Jan 28 2026, ANEB's PE ratio (Price to Earnings) is -4.19 and Price to Sales (PS) ratio is 51.36. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ANEB PE ratio will change depending on the future growth rate expectations of investors.